Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

MERCK & CO., INC. : Ex-dividend day for

12/14/2020 EST

A dividend is removed today from Merck & Co., Inc.'s share.



© Factset 2020
All news about MERCK & CO., INC.
01/26MERCK : Declares Unchanged Quarterly Dividend of $0.65 Per Common Share, Payable..
MT
01/26MERCK : Announces Second-Quarter 2021 Dividend
BU
01/26MERCK : Says Interim Findings From Ongoing Mid-Stage Study Show Potential of Isl..
MT
01/26MERCK : Presents Interim Findings from Phase 2a Clinical Trial Evaluating Invest..
BU
01/26Merck Secures European Commission's Approval of Keytruda as Monotherapy of Co..
MT
01/26MERCK : European Commission Approves Keytruda in Some Colorectal Cancers
DJ
01/26MERCK : European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Tre..
BU
01/26MERCK : Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates, Cont..
AQ
01/25Merck Scraps Covid-19 Vaccine Candidates -- Update
DJ
01/25MERCK : Correction to Merck Scraps Covid-19 Vaccine Candidates Article
DJ
More news
Financials (USD)
Sales 2020 48 203 M - -
Net income 2020 12 158 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 16,9x
Yield 2020 3,05%
Capitalization 203 B 203 B -
EV / Sales 2020 4,53x
EV / Sales 2021 4,17x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 97,05 $
Last Close Price 80,25 $
Spread / Highest target 33,3%
Spread / Average Target 20,9%
Spread / Lowest Target 5,92%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-1.89%203 035
JOHNSON & JOHNSON8.32%436 949
ROCHE HOLDING AG3.82%309 894
NOVARTIS AG2.96%220 401
PFIZER INC.1.36%207 217
ABBVIE INC.3.13%195 085